Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry, FDA Outline Costs Of New MDUFA Proposals; Quality Management A Strong Focus

This article was originally published in Clinica

Executive Summary

After months of discussing proposals on how to improve FDA's device review process in the next user-fee reauthorization (MDUFA IV), the agency put some hard numbers to how much the proposed measures would cost and how many full-time equivalent positions would be required. In total, the agency puts the price tag of the reforms at $500 million over five years on top of the current user fee base, not taking into account inflation.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT103256

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel